A C peptide test (usually written “C-peptide test”) measures how much insulin your body is making. Along with islet-autoantibody tests, it can help clinicians investigate whether diabetes that looks like type 2 may instead be slowly progressive autoimmune diabetes, often called LADA. Neither the person’s appearance nor one test result settles the diagnosis on its own.
When LADA may be considered
LADA is an adult-onset form of autoimmune diabetes in which insulin is not usually needed at diagnosis, though insulin production can decline over time. It may initially be labelled type 2 because blood sugar is high while the person still makes some insulin. The commonly used criteria include adult onset, an islet autoantibody, and no need for insulin for at least six months after diagnosis—but these are not absolute boundaries.
Clues that may raise suspicion include diagnosis before age 50, a personal or family history of autoimmune disease, a BMI below 25, or acute symptoms when diabetes begins. These features are prompts for clinical assessment, not a checklist that can confirm or rule out LADA. People with LADA can also have features that resemble type 2 diabetes.
For more background on how adult-onset type 1 diabetes can resemble type 2, including the overlap in symptoms, see our related guide.
What antibody tests can—and cannot—show
Islet autoantibodies are markers of an immune response directed at insulin-producing cells. GAD antibodies (also called GADA or GAD65 antibodies) are the most commonly detected marker in LADA. Clinicians may also test for other antibodies, such as IA-2 or ZnT8, depending on the situation and local practice.
A positive result can support autoimmune diabetes, especially when clinical features point in that direction. But a single positive result does not always prove that diabetes is autoimmune. A 2021 perspective on LADA cautioned that, in people with few features suggestive of type 1 diabetes, testing in a population where autoimmune diabetes is uncommon can produce misleading positive results. Multiple positive antibodies can make an autoimmune explanation more convincing, but results still need clinical interpretation.
There is a genuine difference in approach: a 2020 international expert panel advised general screening for LADA in newly diagnosed adults who do not need insulin, while other authors have argued for testing people whose clinical features raise suspicion, partly to reduce false-positive interpretation. The panel’s recommendation is expert guidance, not a universally adopted screening rule. Your clinician can weigh your history and the purpose of testing.
What a C peptide test can and cannot tell you
C-peptide is released when the pancreas makes its own insulin, so its level helps estimate how much insulin production remains. It answers a different question from antibody testing: C-peptide reflects insulin secretion, while antibodies help identify an autoimmune process. A C-peptide result alone cannot tell whether the cause is LADA or type 2 diabetes. Levels also need to be read alongside blood glucose and the clinical picture.
An international expert panel led by Raffaella Buzzetti and colleagues proposed using random C-peptide levels to guide LADA treatment decisions: below 0.3 nmol/L, they recommended an insulin regimen like that used for type 1 diabetes; 0.3–0.7 nmol/L was a “gray area”; above 0.7 nmol/L, they suggested a modified type 2 approach with continued monitoring. These are the panel’s proposed categories, not a definitive universal protocol. The authors noted that large clinical trials are lacking.
A higher result may mean insulin production is currently more preserved; it does not rule out a progressive autoimmune process. A lower result can signal less remaining insulin production and may affect treatment planning. Because levels can change, clinicians may repeat C-peptide testing to help reassess care over time.
What to discuss with your clinician
If your diagnosis or response to treatment does not fit the expected pattern, ask whether islet-autoantibody testing or a C-peptide test would clarify the type of diabetes—and how each possible result would change your care. Bring up any autoimmune history, how quickly symptoms developed, and how your glucose levels have changed. Testing can inform treatment and monitoring, but it does not dictate one plan for everyone. The LADA treatment approach remains an area with limited large-scale trial evidence. Seek advice from your diabetes clinician before changing medication or monitoring.






















